Affordable Access

Access to the full text

Role of limonin in anticancer effects of Evodia rutaecarpa on ovarian cancer cells

Authors
  • Bae, Jae Ryul1
  • Park, Wook Ha1
  • Suh, Dong Hoon1
  • No, Jae Hong1
  • Kim, Yong Beom1
  • Kim, Kidong1
  • 1 Seoul National University Bundang Hospital, Seongnam, Republic of Korea , Seongnam (South Korea)
Type
Published Article
Journal
BMC Complementary Medicine and Therapies
Publisher
BioMed Central
Publication Date
Mar 20, 2020
Volume
20
Issue
1
Identifiers
DOI: 10.1186/s12906-020-02890-y
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundOvarian cancer therapy generally involves systemic chemotherapy with anticancer drugs; however, chemotherapy with a platinum-based drug has often been shown to cause adverse reactions and drug resistance in ovarian cancer patients. Evodia rutaecarpa (ER) reportedly shows anticancer activity against various types of cancer cells. However, the effects of ER have not yet been fully uncovered in ovarian cancer.MethodsIn the present study, we investigated the anticancer effects of an ER extract and its components against the ovarian cancer cell lines SKOV-33, A2780, RMUG-S and a cisplatin-resistant SKOV-3 cell line (CisR SKOV-3). Cell viability and colony formation assays along with subcellular fractionation analysis, immunoblotting, and immunofluorescence staining were performed.ResultsER treatment led to a significant reduction in the viability of SKOV-3 cells. Moreover, limonin, a compound found in ER, reduced the viability of both serous-type (SKOV-3 and A2780) and mucinous-type (RMUG-S) ovarian cancer cells by inducing apoptosis via activation of the p53 signaling pathway. Furthermore, limonin reversed the drug resistance through activation of apoptosis in CisR SKOV-3.ConclusionTaken together, our findings suggest that limonin contributes to the anti-ovarian cancer effects of ER by inducing apoptosis via activation of the p53 signaling pathway.

Report this publication

Statistics

Seen <100 times